Clinical trials: Schizo-affective Disorder
Healthy
Study Evaluating Multiple Ascending Dose in Schizophrenia Patients
This is a randomized, inpatient, ascending multiple dose study to assess safety and tolerability of SLV-313 SR tablets administered orally to subjects with schizophrenia and schizoaffective disorder.
- Trial name
- NCT00620568
- Testing
- SLV-313 SR
- Volunteers
- 32 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia / Schizoaffective Disorder
A Cognitive Mobile Intervention for Motivation in Psychotic Disorders
The goal of this study is to develop and test the impact of a smartphone-based working memory cognitive training digital therapeutic for individuals with schizophrenia or a related disorder.
- Trial name
- NCT07674914
- Testing
- Cognitive Training, Mobile cognitive training
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Alabama at Birmingham
Schizophrenia / Schizoaffective Disorder
tACS for Self-Other Boundary in Schizophrenia
This clinical trial investigates whether a non-invasive brain stimulation technique called transcranial alternating current stimulation (tACS) can improve the ability to distinguish between "self" and "others" in patients with…
- Trial name
- NCT07818668
- Testing
- Transcranial Alternating Current Stimulation (tACS)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chunyan Zhu
Schizophrenia
Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective Disorder
This study will evaluate the safety of multiple doses of NSA-789 in subjects with schizophrenia or schizoaffective disorder. This study will also assess how NSA-789 is absorbed and eliminated, and its effect, if any, on the brain.
- Trial name
- NCT00892021
- Testing
- NSA-789
- Where
- United States
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Schizoaffective Disorder, Schizophrenia
Motivational Interviewing to Improve Work Outcomes in Schizophrenia
Many persons with schizophrenia have difficulty getting and keeping a job. This study is designed to compare the benefits of four sessions of motivational interviewing or illness education in increasing employment rates accruing…
- Trial name
- NCT00261716
- Testing
- IPS, IE, VOMI
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizoaffective Disorder
F-18 Altanserin PET Study of Patients Receiving Clozapine
To examine the feasibility of molecular imaging markers in clinical psychopharmacology
- Trial name
- APC (NCT01398189)
- Testing
- clozapine
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Seoul National University Bundang Hospital
Schizophrenia
First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia
The purpose of this study is to assess the safety and tolerability of AMG 579 following a single oral dose administration in healthy subjects (Part A) and in patients with schizophrenia or stable schizoaffective disorder (Part…
- Trial name
- NCT01568203
- Testing
- AMG 579
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Amgen
Psychotic Disorders, Schizoaffective Disorder
Functional Rehabilitation of Older Patients With Schizophrenia
The primary purpose of this project is to evaluate the efficacy of a group therapy intervention, cognitive behavioral social skills training (CBSST), that teaches social functioning skills and cognitive-behavioral compensatory…
- Conditions
- Psychotic Disorders, Schizoaffective Disorder, Schizophrenia
- Trial name
- NCT00237796
- Testing
- Cognitive Behavioral Social Skills Training (CBSST), Goal Focused Supportive Contact (GFSC)
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia, Schizoaffective Disorder
Clinical Estradiol Trial in Women With Schizophrenia
To investigate the 'estrogen-protection' hypothesis by comparing changes in psychotic symptoms between one group of patients receiving standard antipsychotic drug treatment plus placebo and a second matched group receiving…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00206570
- Testing
- Estradiol
- Where
- Australia
- Volunteers
- 100 people
- Sponsor
- Bayside Health
Patient Treated With Lithium, With Bipolar or Schizo-affective Disorder, Hospitalized in a Psychiatric Ward
Validation of the French Version of the Lithium Knowledge Test (LKT)
Lithium is a drug used to treat several psychiatric illnesses. This medication requires particular vigilance because it has a narrow therapeutic margin: the dose necessary to obtain an effective treatment is close to the toxic…
- Trial name
- LKT (NCT06033326)
- Where
- France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Lille
Obesity, Schizophrenia
Lifestyle Modification for Weight Loss in Schizophrenia
The purpose of this study is to find out how effective lifestyle modification group therapy is on reducing body weight when compared to usual care in individuals with schizophrenia and/or schizoaffective disorder.
- Conditions
- Obesity, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT00990925
- Testing
- Nutritional Lifestyle Modification Group, Usual Care
- Where
- United States
- Volunteers
- 149 people
- Sponsor
- Yale University
Schizophrenia, Schizoaffective Disorder
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT07105111
- Testing
- Valbenazine
- Where
- 19 sites in United States
- Volunteers
- 100 people
- Sponsor
- Neurocrine Biosciences
Schizoaffective Disorder, Psychotic Disorder
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.
The purpose of this study is to measure the effectiveness and assess the safety of two dosages of the antipsychotic paliperidone extended-release (ER) in patients who are experiencing an acute episode of schizoaffective disorder.
- Trial name
- NCT00397033
- Testing
- Paliperidone ER
- Volunteers
- 316 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizoaffective Disorder, Schizophrenia
To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
Although currently marketed antipsychotic drugs are useful in the treatment of schizophrenia, efficacy and safety profiles need to be improved.
- Trial name
- NCT00007774
- Testing
- Haloperidol, Olanzapine
- Where
- 18 sites in United States
- Volunteers
- 600 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia, Schizoaffective Disorder
Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia
The study looks at whether treatment with iloperidone (Fanapt) is associated with improvements in social cognition in individuals who have been recently diagnosed with schizophrenia or schizoaffective disorder.
- Trial name
- NCT01929889
- Testing
- Iloperidone
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Northwestern University
Schizophrenia, Schizoaffective Disorder
A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder
Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia.
- Trial name
- Switch Ext (NCT01143090)
- Testing
- Lurasidone HCl
- Where
- 27 sites in United States
- Volunteers
- 149 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Schizoaffective Disorder
Virtual Reality Job Interview Training in Severe Mental Illness
This is a randomized controlled trial to evaluate the community-based effectiveness of virtual reality job interview training (VR-JIT). Northwestern University is partnering with Thresholds Inc.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Depressive Disorder
- Trial name
- NCT03049813
- Testing
- Virtual Reality Job Interview Training, Supported Employment (Services as Usual)
- Where
- 4 sites in United States
- Volunteers
- 168 people
- Sponsor
- University of Michigan
Patient Noncompliance
Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic
Psychotropic medications are a cornerstone of treatment for individuals with schizophrenia and schizoaffective disorder, however rates of full or partial non-adherence can exceed 60%.
- Trial name
- CAE-L (NCT01152697)
- Testing
- haloperidol decanoate, haloperidol, Customized Adherence Enhancement
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University Hospitals Cleveland Medical Center
Schizophrenia, Schizoaffective Disorder
Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS)
The purpose of this study is to prove safety and efficacy of aripiprazole.
- Trial name
- NCT00304655
- Testing
- Aripiprazole
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Schizophrenia, Schizoaffective Disorder
Schizophrenia and the Gut Microbiome
In a sample of 20 inpatients with a DSM-IV-TR/DSM 5 diagnosis of schizophrenia or schizoaffective disorder, investigators propose to conduct a prospective, 2 week observational trial to collect gastrointestinal stool samples in…
- Trial name
- NCT02921243
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Maryland, Baltimore